Liisa Bayko
Stock Analyst at Evercore ISI Group
(2.57)
# 727
Out of 5,340 analysts
90
Total ratings
56.06%
Success rate
33.56%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
CRSP CRISPR Therapeutics | Upgrades: Outperform | 60 99 | 38.79 | 155.22% | 2 | Feb 14, 2025 | |
TVTX Travere Therapeutics | Maintains: Outperform | 33 45 | 16.71 | 169.3% | 5 | Feb 12, 2025 | |
BCRX BioCryst Pharma | Maintains: Outperform | 10 12 | 10.24 | 17.19% | 5 | Jan 13, 2025 | |
EDIT Editas Medicine | Maintains: Outperform | 7 5 | 1.5 | 233.33% | 5 | Dec 16, 2024 | |
CARM CARISMA Therapeutics | Downgrades: In-Line | 4 1 | 0.17 | 311.76% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 7 5 | 3.08 | 62.34% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 30 35 | 26.22 | 33.49% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 405 360 | 291 | 23.71% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 210 260 | 285.13 | -8.81% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 945 70 | n/a | n/a | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: In-Line | 7 2 | 1.2 | 66.67% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 37 33 | 7.77 | 324.71% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 50 38 | 38.86 | -2.21% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 438 | 438.51 | -0.12% | 15 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 60 80 | 35.64 | 124.47% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 18 | 3.96 | 354.55% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 14 25 | 5.58 | 348.03% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 62 | 5.73 | 982.02% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 35 | 5.93 | 490.22% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 24 | 21.23 | 13.05% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 378 | n/a | n/a | 1 | Mar 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Outperform | 30 | 9.2 | 226.09% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Market Outperform | 10 | 3.08 | 224.68% | 1 | Feb 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Market Outperform | 175 | n/a | n/a | 3 | Jan 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Outperform | 10 16 | n/a | n/a | 1 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 20 | n/a | n/a | 1 | May 19, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 1 | Jan 31, 2017 |